Depressive Disorder
Recent clinical, regulatory, research and industry developments relating to this disease.
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression.
Psychedelic therapy in depression and substance use disorders.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q3 2028.
- Q3 2028A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With Seltorexant
- Q4 2028A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
- Q4 2028RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
- Q1 2030Prefrontal Glutamatergic Modulation by N-acetylcysteine and Mindfulness-based Cognitive Therapy for Mild Depression in Youth
- Q1 2030Sequential Multiple Assignment Randomized Trial for Bipolar Depression
Clinical MilestonesView all 15Hide
- 2026-07-06A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or BehaviorResults expected Q2 2031
- 2026-07-06A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With SeltorexantResults expected Q3 2028
- 2026-06-22RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)Results expected Q4 2028
- 2026-03-20A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness SymptomsResults expected Q4 2028
- 2026-03-11Prefrontal Glutamatergic Modulation by N-acetylcysteine and Mindfulness-based Cognitive Therapy for Mild Depression in YouthResults expected Q1 2030
- 2026-06-17A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderCompleted
- 2026-05-16Clonidine to Prevent Postictal Delirium After ElectroConvulsive Therapy: a Randomised, Placebo-controlled, Triple-blind, Single-centre Trial.Completed
- 2026-03-31Neurocomputational Mechanisms of Mood ImprovementCompleted
- 2026-02-17A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum DepressionCompleted
- 2026-01-31Research on the Therapeutic Effect and Clinical Indicators of XingpiJieyu Formula in the Treatment of Severe Liver Depression and Spleen Deficiency Type Depression Based on Abnormal Mitochondrial Energy Metabolism PathwayCompleted
- 2027-05-01Dopamine D3 Receptor Occupancy in Bipolar Depression by Cariprazine (Vraylar): Evaluating Its Antidepressant BenefitWithdrawn
- 2027-03-01A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 As Adjunctive Treatment for Major Depressive Disorder (MDD)Withdrawn
- 2025-10-15The Perinatal SMILES (Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms) Case Series. Combining Ketamine and Interpersonal Psychotherapy to Improve Postpartum MoodWithdrawn
- 2027-05-01ClinicalDopamine D3 Receptor Occupancy in Bipolar Depression by Cariprazine (Vraylar): Evaluating Its Antidepressant BenefitWithdrawn
- 2027-03-01ClinicalA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 As Adjunctive Treatment for Major Depressive Disorder (MDD)Withdrawn
- 2026-07-06ClinicalA Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or BehaviorResults expected Q2 2031
- 2026-07-06ClinicalA Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With SeltorexantResults expected Q3 2028
- 2026-06-22ClinicalRNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)Results expected Q4 2028
- 2026-06-17ClinicalA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderCompleted
- 2026-05-16ClinicalClonidine to Prevent Postictal Delirium After ElectroConvulsive Therapy: a Randomised, Placebo-controlled, Triple-blind, Single-centre Trial.Completed
- 2026-03-31ClinicalNeurocomputational Mechanisms of Mood ImprovementCompleted
- 2026-03-20ClinicalA Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness SymptomsResults expected Q4 2028
- 2026-03-11ClinicalPrefrontal Glutamatergic Modulation by N-acetylcysteine and Mindfulness-based Cognitive Therapy for Mild Depression in YouthResults expected Q1 2030
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resi… (2019)
Approval — Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder. Duloxetine Ze… (2015)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Depressive Disorder8
- Depression3
- Hallucinogens3
- Gastrointestinal Microbiome2
- Stress, Psychological2
- Suicidal Ideation2
- Suicide2
- Adaptation, Psychological1
Leading journals6
- PLoS medicine2
- The British journal of psychiatry : the journal of mental science2
- Translational psychiatry2
- Annual review of psychology1
- Archives of general psychiatry1
- Archives of internal medicine1
Leading researchers8
- Agostini MA1
- Akan M1
- Alexopoulos AV1
- Allen NB1
- Anderson RJ1
- Anderson WS1
- Appelbaum LG1
- Aubry M1
Affiliations (unnormalised)6
- University College London2
- Avicenne Hospital1
- Aziz Sancar Institute of Experimental Medicine1
- Basic Medical College1
- Bezmialem Vakif University1
- Cambridgeshire and Peterborough NHS Foundation Trust1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Depressive disorder is an affective disorder marked by a persistently dysphoric mood or a sustained loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. The literature also treats it as a common condition with important implications for diagnosis, complications, and treatment.
The grounding supports a multifactorial etiology rather than a single cause. Review evidence points to biopsychosocial contributors in late-life depression, and to adverse experiences in childhood, depression and anxiety disorders in childhood and adolescence, sociocultural roles with related adverse experiences, and psychological attributes related to vulnerability to life events and coping skills. The literature also notes longitudinal links with overweight and obesity, but this is presented as an association rather than a proven cause.
The supplied literature indicates shared biological pathways and neurotransmitters between depression and pain, suggesting overlapping mechanisms in comorbid states. It also includes immunology and microbiology as covered aspects, and specifically co-studies the gastrointestinal microbiome, but the grounding does not provide a more detailed mechanism. Depression is also discussed in relation to stress, psychological adaptation, anxiety, and suicidal ideation, indicating involvement of stress-related and psychological processes.
Female sex is associated with higher prevalence, incidence, and morbidity risk beginning at mid-puberty and continuing through adult life. Adverse experiences in childhood, depression and anxiety disorders in childhood and adolescence, sociocultural roles with related adverse experiences, and psychological vulnerability to life events and coping difficulties are identified as likely contributors. Overweight and obesity are also longitudinally associated with depression in the reviewed literature.
The grounding supports treatment at the level of therapy, drug therapy, and prevention and control, but does not provide specific regimens. It also indicates that antidepressant medications are used, with evidence reviewed for their benefits, and that therapy evidence has expanded in late-life depression. Psilocybin is co-studied, but the supplied material does not establish it as standard care.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.